Arkansas legislation · 95th General Assembly (2025 Regular)
Arkansas HB1055: TO ESTABLISH COVERAGE DIAGNOSIS AND TREATMENT TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE OR OTHER DEMENTIA-RELATED DISEASE UNDER THE STATE AND PUBLIC SCHOOL LIFE AND HEALTH INSURANCE PROGRAM
Status: Failed, May 5, 2025
What the bill says
An act to be entitled an act to establish coverage diagnosis and treatment to slow the progression of alzheimer's disease or other dementia-related disease under the state and public school life and health insurance program; and for other purposes. subtitle to establish coverage diagnosis and treatment to slow the progression of alzheimer's disease or other dementiarelated disease under the state and public school life and health insurance program.
From the introduced text:
An Act To Be Entitled AN ACT TO ESTABLISH COVERAGE DIAGNOSIS AND TREATMENT TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE OR OTHER DEMENTIA-RELATED DISEASE UNDER THE STATE AND PUBLIC SCHOOL LIFE AND HEALTH INSURANCE PROGRAM; AND FOR OTHER PURPOSES. Subtitle TO ESTABLISH COVERAGE DIAGNOSIS AND TREATMENT TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE OR OTHER DEMENTIARELATED DISEASE UNDER THE STATE AND PUBLIC SCHOOL LIFE AND HEALTH INSURANCE PROGRAM. BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS: SECTION 1. Arkansas Code Title 21, Chapter 5, Subchapter 4, is amended to add an additional section to read as follows: 21-5-425. Coverage for diagnosis and treatment of Alzheimer's disease or other dementia-related disease -- Legislative findings and intent -- Rules. (a) The General Assembly finds that: (1) Alzheimer's disease is the seventh leading cause of death in Arkansas according to the Centers for Disease Control and Prevention; (2) The cost of managing the complications of late-stage Alzheimer's disease, largely due to delayed diagnosis and access to treatment, outweighs the cost of expeditious and effective treatment; (3) The diagnosis and treatment of Alzheimer's disease or other *ANS058* 01-30-2025 10:13:32 ANS058 As Engrossed: H1/30/25 HB1055 dementia-related disease should be a clinical decision made by a physician based on evidence-based guidelines; and (4) The United States Food and Drug Administration has granted …